Help patients say 'yes' to more moments

CM, chronic migraine; EM, episodic migraine; LT, long-term.

With AJOVY®, patients may experience significantly fewer affected days from Baseline vs placebo1-3

In the HALO EM and CM trials monthly average number of affected days were reduced by:

Fewer affected days from Baseline vs placebo were seen as early as Week 11-3

 

 

HALO: EPISODIC MIGRAINE

Mean reduction from Baseline in average monthly migraine days1,2

HALO: Chronic Migraine
Mean reduction from Baseline in average monthly headache days of at least moderate severity1,3

Secondary endpoints:

 

AJOVY® reduced migraine days by ≥50% from Baseline in the majority of patients4

LT, long-term

Created using data from Newman LC et al. 20194

Even patients with difficult-to-treat migraine* can achieve ≥50% reduction in migraine days from Baseline with AJOVY®6

*Patients with difficult-to-treat migraine were episodic and chronic migraine patients who had documented failure to 2–4 classes of migraine preventive medications. Documented failure was defined as at least one of the following: Lack of efficacy after at least 3 months of therapy at a stable dose, patient cannot tolerate the drug, drug is contraindicated for the patient, or drug is not suitable for the patient.6

Even in patients with difficult-to-treat migraine,* AJOVY® significantly reduced monthly migraine days vs placebo6

In the FOCUS trial the monthly average number of migraine days was reduced by:

*Patients with difficult-to-treat migraine were episodic and chronic migraine patients who had documented failure to 2–4 classes of migraine preventive medications.
Documented failure was defined as at least one of the following: Lack of efficacy after at least 3 months of therapy at a stable dose, patient cannot tolerate the drug, drug is contraindicated for the patient, or drug is not suitable for the patient.6

Help patients say ‘yes’ to more moments at work, in study and at home

*At Month 12 after the first injection in HALO LT, MIDAS scores were reduced by 27.4 points from Baseline (Baseline score: 38.0) with AJOVY® monthly, and 26.0 points from Baseline (Baseline score: 41.7) with AJOVY® quarterly.2,7
†At Month 12 after the first injection in HALO LT, HIT-6 scores were reduced by 8.4 points from Baseline (Baseline score: 64.6) with AJOVY® monthly, and 7.8 points from Baseline (Baseline score: 64.3) with AJOVY® quarterly.3,7 
A clinically meaningful improvement in patients with chronic daily headache is defined as at least a 2.3-point reduction in HIT-6 score.8
HIT-6, six-item headache impact test; LT, long-term; MIDAS, migraine disability assessment. 

Suggestions to explore next

Continue to Flexibility page of AJOVY

Flexibility to help you meet your patients’ needs1,6

Felxibility of ajovy®

AJOVY® was evaluated in four Phase III clinical trials (the HALO and FOCUS studies)2,3,6,10,11 

Clinical trial designs
Continue to Safety page of AJOVY

A generally well-tolerated treatment choice1–4,6 

safety profile of ajovy®